Pan­cre­at­ic can­cer study fail­ure crip­ples a Mer­ri­mack drug, forc­ing a coup de grâce and pipeline re­treat

Eigh­teen months af­ter Mer­ri­mack $MACK re­struc­tured, sell­ing off its one mar­ket­ed drug, switch­ing out CEOs and cir­cling the wag­ons around three key can­cer drugs, the biotech has been forced to scut­tle one of its pri­or­i­ty drug pro­grams.

MM-141 (is­ti­ra­tum­ab), has failed a Phase II pan­cre­at­ic can­cer study af­ter in­ves­ti­ga­tors paired it with nab-pa­cli­tax­el and gem­c­itabine against the stan­dard com­bo alone. There are no da­ta in the state­ment, but the com­pa­ny said the drug flat failed on the pri­ma­ry and sec­ondary end­points, with noth­ing en­cour­ag­ing to re­port in the sub­group analy­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA